The IGFBP-3 assays allow sensitive determination of the concentration of IGFBP-3 in human serum and other sample matrices such as urine, follicular fluid and seminal fluid. Serum IGFBP-3 concentration is influenced by growth hormone, age, sexual development stage, diet, hypothyroidism, diabetes mellitus, liver and kidney functions. In clinical diagnostics, serum IGFBP-3 concentration can be used to diagnose growth hormone deficiency and excess.

A major biological activity of IGFBP molecules is, among others, the binding and targeted release of IGF-I. Various studies have shown that increased IGFBP-3 fragmentation occurs in catabolic situations (sepsis, trauma), burns, tumor diseases, but also during pregnancy. Mediagnost therefore offers a Ligand binding assay (E04A), which detects only IGFBP-3 that is capable of binding IGF-I.

IGFBP-3
ELISA RIA-CT LIA
Product number

E03A

R11

E04A

Regulatory status

IVD

IVD RUO
Reference material
Incubation period 2,5h 15h 3,5h
Antibody Rabbit Rabbit Rabbit
Calibrator native IGFBP-3 native IGFBP-3 native IGFBP-3
Assay Range
[µg/L]
0,03 – 15150 0,8 – 24000 0,18 – 15150
Samples

Serum
EDTA / Heparin Plasma

Serum
EDTA / Heparin Plasma
Serum
EDTA / Heparin Plasma
Sample dilution 1:505 1:301 1:505
analyt. Sensitivity
[µg/L]
0,03 0,8 0,18
Intra-/Interassay Variance [%] <10 <10 <10
Package insert PDF icon PDF icon PDF icon
Reference values Blum WF, Ranke MB (1990) Use of insulin-like growth factor binding protein 3 for the evaluation of growth disorders. Horm Res 34 (Suppl):31-37